Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Accumulated Expenses (2021 - 2026)

Longeveron (LGVN) posted quarterly Accumulated Expenses of $2.9 million for Q1 2026, up 77.35% year-over-year from $1.6 million in Q1 2025, and down 1.62% quarter-over-quarter from $3.0 million in Q4 2025.

Longeveron (LGVN) Accumulated Expenses (2021 - 2026) Analysis & Trends

Longeveron's Accumulated Expenses history runs 6 years deep, the most recent figure standing at $2.9 million for Q1 2026.

  • In Q1 2026, Accumulated Expenses rose 77.35% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 77.35% YoY), while the FY2025 annual figure was $3.0 million, up 63.13% from the prior year.
  • Accumulated Expenses for Q1 2026 stood at $2.9 million, down from $3.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $3.2 million in Q3 2025, with the low at $613000.0 in Q1 2023.
  • The 5-year median for Accumulated Expenses is $1.7 million (2024), against an average of $1.9 million.
  • The sharpest annual moves came in 2022 and 2024: Accumulated Expenses tumbled 51.02% in 2022, then soared 291.68% in 2024.
  • Longeveron's Accumulated Expenses stood at $650000.0 in 2022, then jumped by 231.08% to $2.2 million in 2023, then fell by 15.43% to $1.8 million in 2024, then surged by 63.13% to $3.0 million in 2025, then retreated by 1.62% to $2.9 million in 2026.
  • Business Quant data shows LGVN's Accumulated Expenses at $2.9 million in Q1 2026, $3.0 million in Q4 2025, and $3.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 2.65 Mn
Mar 31, 2026 2.92 Mn
Dec 31, 2025 2.97 Mn
Sep 30, 2025 3.17 Mn
Jun 30, 2025 1.91 Mn
Mar 31, 2025 1.65 Mn
Dec 31, 2024 1.82 Mn
Sep 30, 2024 1.48 Mn
Jun 30, 2024 1.61 Mn
Mar 31, 2024 2.40 Mn
Dec 31, 2023 2.15 Mn
Sep 30, 2023 1.47 Mn
Jun 30, 2023 1.31 Mn
Mar 31, 2023 613,000.00
Dec 31, 2022 650,000.00
Dec 31, 2021 1.33 Mn